| |
| Trade Name | COBAS® AMPLIPREP/COBAS® TAQMAN® CMV TEST (CAP/CTM CMV TEST) |
| Classification Name | cytomegalovirus (cmv) dna quantitative assay |
| Applicant | ROCHE MOLECULAR SYSTEMS, INC. |
| PMA Number | P110037 |
| Date Received | 10/24/2011 |
| Decision Date | 07/05/2012 |
| Product Code | |
| Docket Number | 12M-0713 |
| Notice Date | 07/11/2012 |
| Advisory Committee |
Microbiology |
| Expedited Review Granted? | No |
| Combination Product |
No
|
| Information About: |
Labeling, Approval Order, Summary of Safety and Effectiveness |
Approval Order Statement Approval for the cobas ampliprep/cobas taqman cmv test. This device is indicated for: the cobas ampliprep/cobas taqman cmv test is an in vitro nucleic acid amplification test for the quantitative measurement of cytomegalovirus (cmv) dna in human edta plasma using the cobas ampliprep instrument for automated specimen processing and the cobas taqman analyzer or the cobas taqman 48 analyzer for automated amplification and detection. The cobas ampliprep/ cobas taqman cmv test is intended for use as an aid in the management of solid-organ transplant patients who are undergoing anti-cmv therapy. In this population serial dna measurements can be used to assess virological response to antiviral treatment. The results from the cobas ampliprep/cobas taqman cmv test must be interpreted within the context of all relevant clinical and laboratory findings. The cobas ampliprep/cobas taqman cmv test is not intended for use as a screening test for the presence of cmv dna in blood or blood products. |
| Approval Order |
Approval Order
|
| Supplements: |
S001 S002 S003 S004 S005 S006
|